Overview

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Texas at Austin
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Isradipine